Search
Corticotropin
go.drugbank.com/drugs/DB01285ApprovedInvestigationalVet approvedCorticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis.
Tofersen
go.drugbank.com/drugs/DB14782ApprovedInvestigational[A259028,A259033] Tofersen was granted accelerated approval from the FDA on April 25, 2023, as the first treatment for adults with ALS caused by SOD1 mutation. … [A259023] However, it could potentially be due to the short timeframe of tofersen treatment, and more longterm trials are being conducted to confirm this hypothesis.[A259023]
Synonyms: DNA, D((2'-O-(2-METHOXYETHYL))M5RC-SP-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-SP-T-SP-A-SP-M5C-SP-A-SP-T-SP-T-SP-T-SP-M5C-SP-T-SP-A-SP, -(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))RCefiderocol
go.drugbank.com/drugs/DB14879ApprovedInvestigational[L10893] It is indicated for use in complicated urinary tract infections in patients with limited or no alternative treatments available. … [A189057] It represents a significant addition to antibacterial treatment option as it has proven to be effective *in vitro* against multidrug resistant strains including extended spectrum β-lactamase
Deucravacitinib
go.drugbank.com/drugs/DB16650ApprovedInvestigational[A246943] Deucravacitinib was first approved by the FDA in September 2022 to treat moderate-to-severe plaque psoriasis. … to this therapeutic target.
Tinzaparin
go.drugbank.com/drugs/DB06822ApprovedInvestigationalTinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. … LMWHs are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.
Lasmiditan
go.drugbank.com/drugs/DB11732ApprovedInvestigational[A187316,A187322] Lasmiditan, in contrast, is a highly selective agonist of 5-HT<sub>1F</sub> receptors, carrying virtually no affinity for other receptors which appear to be largely responsible for … [sumatriptan]) have seen preferential use in the acute treatment of migraines due to their relatively favourable efficacy and safety.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeMethocarbamol
go.drugbank.com/drugs/DB00423ApprovedInvestigationalVet approved[A178450] Methocarbamol tablets and intramuscular injections are prescription medicines indicated in the United States as an adjunct to rest, physical therapy, and other measures for the relief of discomforts … [L6295] A combination product with [acetylsalicylic acid] and [codeine] is available in Canada by prescription.[L6295] Methocarbamol was FDA approved on 16 July 1957.[L6265]
Mixtures: ROBAXIFEN® NF, ROBAXIFEN® NFTestolactone
go.drugbank.com/drugs/DB00894ApprovedWithdrawnAn antineoplastic agent that is a derivative of progesterone and used to treat advanced breast cancer.
Sotatercept
go.drugbank.com/drugs/DB12118ApprovedInvestigational[L50361] Sotatercept works to resolve the imbalance in activin–growth differentiation factor and BMP pathway signalling observed in PAH. … It is a homodimeric recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA (ActRIIA) linked to the human IgG1 Fc domain.
Fluoxetine
go.drugbank.com/drugs/DB00472ApprovedInvestigationalVet approved[A181673] It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies
Synonyms: (+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine, (+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-P-tolyl)oxy)propylamineCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome